Literature DB >> 28799949

Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching.

James Trauer1, Stephen Muhi, Emma S McBryde, Shmeylan A Al Harbi, Yaseen M Arabi, Andrew J Boyle, Rodrigo Cartin-Ceba, Wei Chen, Yung-Tai Chen, Marco Falcone, Ognjen Gajic, Jack Godsell, Michelle Ng Gong, Daryl Kor, Wolfgang Lösche, Daniel F McAuley, Hollis R O'Neal, Michael Osthoff, Gordon P Otto, Maik Sossdorf, Min-Juei Tsai, Juan C Valerio-Rojas, Tom van der Poll, Francesco Violi, Lorraine Ware, Andreas F Widmer, Maryse A Wiewel, Johannes Winning, Damon P Eisen.   

Abstract

OBJECTIVE: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. STUDY SELECTION: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. DATA SOURCES: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. DATA EXTRACTION: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. DATA SYNTHESIS: Use of aspirin was associated with a 7% (95% CI, 2-12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I = 61.6%).
CONCLUSIONS: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28799949      PMCID: PMC5640482          DOI: 10.1097/CCM.0000000000002654

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  40 in total

Review 1.  Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation.

Authors:  D Cox; S W Kerrigan; S P Watson
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

2.  Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study.

Authors:  Min-Juei Tsai; Shuo-Ming Ou; Chia-Jen Shih; Pei-Wen Chao; Lan-Fu Wang; Yu-Ning Shih; Szu-Yuan Li; Shu-Chen Kuo; Yen-Tao Hsu; Yung-Tai Chen
Journal:  Intensive Care Med       Date:  2015-04-01       Impact factor: 17.440

3.  Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis.

Authors:  Damon P Eisen; David Reid; Emma S McBryde
Journal:  Crit Care Med       Date:  2012-06       Impact factor: 7.598

4.  Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock.

Authors:  Gordon Philipp Otto; Maik Sossdorf; Janina Boettel; Björn Kabisch; Hannes Breuel; Johannes Winning; Wolfgang Lösche
Journal:  Platelets       Date:  2012-09-20       Impact factor: 3.862

5.  Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis.

Authors:  Wei Chen; David R Janz; Julie A Bastarache; Addison K May; Hollis R O'Neal; Gordon R Bernard; Lorraine B Ware
Journal:  Crit Care Med       Date:  2015-04       Impact factor: 7.598

6.  Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data.

Authors:  Sameer S Kadri; Chanu Rhee; Jeffrey R Strich; Megan K Morales; Samuel Hohmann; Jonathan Menchaca; Anthony F Suffredini; Robert L Danner; Michael Klompas
Journal:  Chest       Date:  2016-07-22       Impact factor: 9.410

Review 7.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.

Authors:  Sreenivasa Rao Kondapally Seshasai; Shanelle Wijesuriya; Rupa Sivakumaran; Sarah Nethercott; Sebhat Erqou; Naveed Sattar; Kausik K Ray
Journal:  Arch Intern Med       Date:  2012-01-09

8.  Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin.

Authors:  Marco Falcone; Alessandro Russo; Roberto Cangemi; Alessio Farcomeni; Camilla Calvieri; Francesco Barillà; Maria Gabriella Scarpellini; Giuliano Bertazzoni; Paolo Palange; Gloria Taliani; Mario Venditti; Francesco Violi
Journal:  J Am Heart Assoc       Date:  2015-01-06       Impact factor: 5.501

9.  Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis.

Authors:  Andrew J Boyle; Stefania Di Gangi; Umar I Hamid; Linda-Jayne Mottram; Lia McNamee; Griania White; L J Mark Cross; James J McNamee; Cecilia M O'Kane; Daniel F McAuley
Journal:  Crit Care       Date:  2015-03-23       Impact factor: 9.097

10.  Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study.

Authors:  Juan C Valerio-Rojas; Insara J Jaffer; Daryl J Kor; Ognjen Gajic; Rodrigo Cartin-Ceba
Journal:  Crit Care Res Pract       Date:  2013-02-20
View more
  12 in total

1.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.

Authors:  Marco Falcone; Alessandro Russo; Yuichiro Shindo; Alessio Farcomeni; Filippo Pieralli; Roberto Cangemi; Jinliang Liu; Jingyan Xia; Junya Okumura; Masahiro Sano; Christopher Jones; Vieri Vannucchi; Massimo Mancone; Scott Micek; Feng Xu; Francesco Violi; Marin Kollef
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia.

Authors:  Josh Sun; Satoshi Uchiyama; Joshua Olson; Yosuke Morodomi; Ingrid Cornax; Nao Ando; Yohei Kohno; May M T Kyaw; Bernice Aguilar; Nina M Haste; Sachiko Kanaji; Taisuke Kanaji; Warren E Rose; George Sakoulas; Jamey D Marth; Victor Nizet
Journal:  Sci Transl Med       Date:  2021-03-24       Impact factor: 19.319

4.  Aspirin use and long-term rates of sepsis: A population-based cohort study.

Authors:  Joann Hsu; John P Donnelly; Ninad S Chaudhary; Justin X Moore; Monika M Safford; Junghyun Kim; Henry E Wang
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

Review 5.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Authors:  Vanessa Bianconi; Francesco Violi; Francesca Fallarino; Pasquale Pignatelli; Amirhossein Sahebkar; Matteo Pirro
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

6.  Treatment With Acetylsalicylic Acid Reverses Endotoxin Tolerance in Humans In Vivo: A Randomized Placebo-Controlled Study.

Authors:  Guus P Leijte; Dorien Kiers; Wouter van der Heijden; Aron Jansen; Jelle Gerretsen; Verin Boerrigter; Mihai G Netea; Matthijs Kox; Peter Pickkers
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

Review 7.  Early Host Interactions That Drive the Dysregulated Response in Sepsis.

Authors:  Steven W Kerrigan; Tatyana Devine; Glenn Fitzpatrick; Jecko Thachil; Dermot Cox
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

8.  Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.

Authors:  Udaya S Tantry; Karsten Schror; Eliano Pio Navarese; Young-Hoon Jeong; Jacek Kubica; Kevin P Bliden; Paul A Gurbel
Journal:  J Exp Pharmacol       Date:  2021-12-07

9.  Aspirin for Sepsis Prophylaxis: An Ounce of Prevention?

Authors:  Jonathan D Casey; Matthew W Semler; Julie A Bastarache
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

10.  Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.

Authors:  Damon P Eisen; Karin Leder; Robyn L Woods; Jessica E Lockery; Sarah L McGuinness; Rory Wolfe; David Pilcher; Elizabeth M Moore; Adithya Shastry; Mark R Nelson; Christopher M Reid; John J McNeil; Emma S McBryde
Journal:  Lancet Respir Med       Date:  2020-09-17       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.